Monitoring Patients With Iron Deficiency Anemia After Diagnosis

Panelists discuss how monitoring patients with iron deficiency anemia requires regular follow-up appointments to track laboratory values, assess symptom improvement (particularly fatigue), and evaluate treatment response while considering the impact of comorbid conditions, with adjustments to therapy made based on both objective markers and patient-reported outcomes.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

Now Viewing

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

EP: 8.Factoring in Safety Considerations With IV Iron Products

EP: 9.Adverse Effects Associated With Hypophosphatemia

EP: 10.Clinical Impact of Hypophosphatemia

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• How are patients with IDA monitored after they have been diagnosed, and what is your approach to follow-up appointments?
• How do you monitor for improvements in fatigue in IDA while factoring in other comorbidities?

Related Videos

Related Content

Advertisement

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 25th 2025

New Therapies Expanding the MASH Treatment Landscape

Jared Kaltwasser

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 24th 2025

Medicare $2 Drug List Model Could Have Reduced 2021 Out-of-Pocket Generic Costs

Brooke McCormick

The researchers emphasized the need for ongoing research and advocacy to further address drug affordability.

March 23rd 2025

Systemic Immune Response Index Identified as Independent Risk Factor for COPD

Brooke McCormick

The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary disease (COPD).

Related Content

Advertisement

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 25th 2025

New Therapies Expanding the MASH Treatment Landscape

Jared Kaltwasser

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 24th 2025

Medicare $2 Drug List Model Could Have Reduced 2021 Out-of-Pocket Generic Costs

Brooke McCormick

The researchers emphasized the need for ongoing research and advocacy to further address drug affordability.

March 23rd 2025

Systemic Immune Response Index Identified as Independent Risk Factor for COPD

Brooke McCormick

The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary disease (COPD).